Comparing the efficacy of food and pharmaceutical bioactivecompounds in the management of Alzheimer’s disease
##doi.readerDisplayName##:
https://doi.org/10.31989/afbc.v2i7.1678摘要
Alzheimer's disease (AD) is a progressive neurodegenerative condition and a growing global health burden, especially among aging populations. Despite ongoing therapeutic advancements, current pharmaceutical treatments remain limited in their ability to prevent, halt, or reverse disease progression. Bioactive compounds, derived from both food and pharmaceutical sources, are emerging as promising agents for AD intervention due to their diverse biological activities and mechanisms of action.
This review critically synthesizes current evidence on the therapeutic potential of bioactive compounds for AD, focusing on comparing pharmaceutical agents and food-derived compounds. Pharmaceutical bioactives often provide targeted symptom relief but are associated with limited disease-modifying effects and potential adverse reactions. Conversely, food-derived bioactive compounds demonstrate growing promise in promoting long-term neuroprotection and prevention, supported by favorable safety profiles and multi-targeted actions.
By directly contrasting these two categories, this review highlights the unique therapeutic potential of dietary bioactives and underscores the need for a paradigm shift in Alzheimer’s research, from symptom management to long-term prevention strategies. This comparative analysis emphasizes the importance of shifting research priorities from short-term symptom management to long-term prevention strategies. It advocates for a more integrative approach that includes dietary bioactives as part of comprehensive AD care.
Novelty: This review uniquely highlights a critical comparative analysis between food and pharmaceutical bioactive compounds in AD therapy. It advocates for a strategic re-evaluation of research priorities from solely symptom alleviation to long-term disease prevention, thereby illuminating the undervalued role of dietary bioactives.
Keywords: Alzheimer’s disease, bioactive compounds, food-derived bioactives, pharmaceutical interventions, neuroprotection, functional food, Pharmaceutical Bioactive Compounds
##submission.downloads##
已出版
期次
栏目
##submission.license##
##submission.copyrightStatement##
##submission.license.cc.by-nc4.footer##Any manuscripts or substantial parts of it, submitted to the journal must not be under consideration by or previously published in any other journal or citable form. Authors are required to ensure that no material submitted as part of a manuscript infringes existing copyrights or the rights of a third party. In submitting one's article in any form, the author has assigned the FFC publishing rights and has agreed to an automatic transfer of the copyright to the publisher. This is so that the FFC may create print option journals, for example, at the FFC’s discretion. If the author wishes to distribute their works by means outside of the FFC, for example within their community, they will have to place a request.
Correspondence concerning articles published in Functional Foods in Health and Disease is encouraged. While derivative works (adaptations, extensions on the current work, etc.) are allowed, distribution of the modified material is not allowed without permission from the FFC.